News & Updates

Show Multimedia Only

Tislelizumab plus nab-paclitaxel shows therapeutic potential against bladder cancer

18 Mar 2025

Treatment with the combination of the immune checkpoint inhibitor tislelizumab plus low-dose nab-paclitaxel exerts promising antitumour activity in patients with very high risk non–muscle-invasive bladder cancer who are ineligible for or decline radical cystectomy, according to the results of the phase II TRUCE-02 trial.

Tislelizumab plus nab-paclitaxel shows therapeutic potential against bladder cancer

18 Mar 2025

Social vulnerability implicated in urinary incontinence burden in women

14 Mar 2025

Women who are socially vulnerable appear to have worse urinary incontinence and poorer incontinence-related quality of life, according to a study.

Social vulnerability implicated in urinary incontinence burden in women

14 Mar 2025

Ureteral stent omission safe, feasible in RARC-IC

14 Mar 2025

A recent study has shown the safety and feasibility of omitting ureteral stent placement during robot-assisted radical cystectomy with intracorporeal ileal conduit (RARC-IC).

Ureteral stent omission safe, feasible in RARC-IC

14 Mar 2025

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

14 Mar 2025

Using tranexamic acid (TXA) appears to lessen blood loss and the need for perioperative blood transfusion (PBT) without increasing the risk of venous thromboembolism (VTE) in patients with bladder cancer undergoing radical cystectomy, reports a study.

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

14 Mar 2025

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

Impulse control tied to ejaculation time in men with PE

13 Mar 2025

Impulse control appears to be associated with ejaculation time in men with premature ejaculation (PE), suggest the results of a cross-sectional observational study.

Impulse control tied to ejaculation time in men with PE

13 Mar 2025

Remnant cholesterol linked to low testosterone in men

13 Mar 2025

A close association exists between remnant cholesterol (RC) and the risk of low testosterone levels in adult men, suggests a nationwide study.

Remnant cholesterol linked to low testosterone in men

13 Mar 2025

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

11 Mar 2025

In patients with oligometastatic hormone-sensitive prostate cancer, the combination of stereotactic body radiotherapy (SBRT) plus a short course of androgen deprivation therapy (ADT) appears to improve progression-free survival (PFS), according to the phase II RADIOSA trial.

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

11 Mar 2025

Efficacy benefit of nivolumab plus cabozantinib combo in aRCC continues through final results

11 Mar 2025 by

The long-term efficacy benefit of the nivolumab and cabozantinib combination vs sunitinib as a frontline treatment for aRCC is observed through the final results of CheckMate 9ER, with the report covering a minimum follow-up of 5 years first presented at ASCO GU 2025

Efficacy benefit of nivolumab plus cabozantinib combo in aRCC continues through final results

11 Mar 2025

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

10 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Tislelizumab plus nab-paclitaxel shows therapeutic potential against bladder cancer

Tislelizumab plus nab-paclitaxel shows therapeutic potential against bladder cancer

Social vulnerability implicated in urinary incontinence burden in women

Social vulnerability implicated in urinary incontinence burden in women

Ureteral stent omission safe, feasible in RARC-IC

Ureteral stent omission safe, feasible in RARC-IC

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

TXA use in radical cystectomy reduces bleeding, need for blood transfusion

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Impulse control tied to ejaculation time in men with PE

Impulse control tied to ejaculation time in men with PE

Remnant cholesterol linked to low testosterone in men

Remnant cholesterol linked to low testosterone in men

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

Efficacy benefit of nivolumab plus cabozantinib combo in aRCC continues through final results

Efficacy benefit of nivolumab plus cabozantinib combo in aRCC continues through final results

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Original New Drug Application Approvals by US FDA (1-15 February 2025)